Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: Lancet Microbe. 2020 Jun 8;1(2):e84–e92. doi: 10.1016/s2666-5247(20)30011-2

Table 2:

Early bactericidal activities based on Log10 transformed CFU counts and TTP in hours by arm

		Primary Endpoint, CFU (n=62^*)			Secondary Endpoint, TTP (n=63)
Arm No.	Treatment Arm	EBA_0–2 Mean (95% CI)	EBA_2–14 Mean (95% CI)	EBA_0–14 Mean (95% CI)	EBA_0–2 Mean (95% CI)	EBA_2–14 Mean (95% CI)	EBA_0–14 Mean (95% CI)

1	HRZE_1–14	0.22 (0.02, 0.42)	0.11 (0.06, 0.16)	0.13 (0.09, 0.16)	34 (26, 42)	9 (6, 12)	13 (10, 15)
2	HRZE_1–2-RZE_3–14	0.30 (0.09, 0.51)	0.12 (0.07, 0.17)	0.14 (0.11, 0.18)	29 (21, 38)	9 (7, 12)	12 (9, 15)
3	HRZE_1–2-MRZE_3–14	0.13 (−0.09, 0.35)	0.14 (0.08, 0.19)	0.13 (0.09, 0.17)	29 (20, 37)	13 (10, 16)	15 (12, 18)
	Arms 1, 2 and 3 combined	0.22 (0.10, 0.34)	-	-	31 (26, 35)	-	-
4	RZE_1–14	0.03 (−0.16, 0.23)	0.13 (0.09, 0.18)	0.12 (0.08, 0.15)	22 (14, 30)	10 (7, 12)	11 (9, 14)

^*

Although 62 participants were eligible for the primary endpoint analysis.